GSK's U.S. Advair sales plummet 22% in Q1--and that's without generics

GlaxoSmithKline's ($GSK) respiratory woes continued in Q1, with stateside sales of aging blockbuster Advair sinking 22%. The company has pricing pressure to thank for that slide, and the med's woes are only set to continue: Generic Advair copies in the U.S. could soon be on their way, the company acknowledged, predicting core EPS would decline at a percentage rate in the high teens as Advair struggles. More from FiercePharma